Dear Users,

The journal ratings for Impact Factor 2024 have been published.

https://jcr.clarivate.com

Viczján Gábor

University of Debrecen Faculty of Medicine

Department of Pharmacology and Pharmacotherapy

2018-

Publication list

Tudóstér co-authors statistics filterable publication list

Export to RIS (EndNote, Mendeley, RefWorks, Zotero etc.)

Upload publications

Request certified publication list

Uploaded publications:

Publications in DEA:

OA:

Date range:

2019-2026

2026

Oláh, B., Tarjányi, V., Viczján, G., Óvári, I., Csótó, A., Szilvássy, Z., Juhász, B., Zsuga, J., Gesztelyi, R., Erdei, T. D.: The ability of SABRE, a new quantitative receptor function model, to quantify receptor binding from even challenging concentration-effect data with a single unified fit.
Front. Pharmacol. 17, 1-6, (article identifier: 1715771), 2026.

doi DEA WoS Scopus

Journal metrics:

Q1 Pharmacology (2025)

Q1 Pharmacology (medical) (2025)

2025

Óvári, I., Pluzsnyik, É., Kiss, R., Lelesz, B., Hegedűs, C., Leiter, I., Erdei, T. D., Viczján, G., Szilvássy, Z., Juhász, B., Gesztelyi, R.: Effects of Lutein and Zeaxanthin on Endothelial Function in Aging Sprague-Dawley Rats.
In: Programme Oral & Poster Abstracts - International Pharmacology Conference : focus on drug discovery and innovation : HUPHAR 2025 Mátraháza 4-6, June. Kiadta: a Magyar Kísérletes és Klinikai Farmakológiai Társaság, HUPHAR, [S.l.], 190, 2025.

DEA

Oláh, B., Tarjányi, V., Takács, B., Pluzsnyik, É., Viczján, G., Óvári, I., Szilvássy, Z., Juhász, B., Zsuga, J., Erdei, T. D., Gesztelyi, R.: The flexibility of SABRE, a new quantitative receptor function model, when fitting challenging concentration-effect data.
Front. Pharmacol. 16, 1-13, (article identifier: 1591761), 2025.

doi DEA WoS Scopus

Journal metrics:

Q1 Pharmacology

Q1 Pharmacology (medical)

Óvári, I., Brezniczky, Á. B., Laczovics, A., Berényi, E., Erdei, T. D., Ojo, O., Hornok, B., Juhász, B., Szilvássy, Z., Zsuga, J., Viczján, G., Gesztelyi, R.: The interaction of AB-680, a CD73 inhibitor, with NBTI, a nucleoside transporter inhibitor, on the adenosinergic control of atrial contractility.
Front. Pharmacol. 16, 1-11, (article identifier: 1683950), 2025.

doi DEA WoS Scopus

Journal metrics:

Q1 Pharmacology

Q1 Pharmacology (medical)

2024

Karácsonyi, Z., Erdei, T. D., Viczján, G., Óvári, I.: A polifarmáciás idős betegek gyógyszerészi gondozásának gazdasági előnyei.
egis. 3 (3), 31-39, 2024.

doi DEA

Papp, C., Mikáczó, A., Szabó, J., Móré, E. C., Viczján, G., Gesztelyi, R., Zsuga, J.: Mesocorticolimbic and Cardiometabolic Diseases: Two Faces of the Same Coin?.
Int. J. Mol. Sci. 25 (17), 1-17, (article identifier: 9682), 2024.

doi DEA WoS Scopus

Journal metrics:

Q2 Catalysis

Q1 Computer Science Applications

Q1 Inorganic Chemistry

Q1 Medicine (miscellaneous)

Q2 Molecular Biology

D1 Organic Chemistry

Q1 Physical and Theoretical Chemistry

D1 Spectroscopy

Óvári, I., Viczján, G., Bege, M., Borbás, A., Herczegh, P., Zsuga, J., Papp, Z., Szilvássy, Z., Juhász, B., Gesztelyi, R., Erdei, T. D.: The ex vivo effects of hypoxanthine-tricyclano, a synthetic adenosine analogue, on rat left and right atria.
Gen. Physiol. Biophys. 43 (6), 577-584, 2024.

doi DEA Scopus

Journal metrics:

Q3 Biophysics

Q3 Medicine (miscellaneous)

Q4 Physiology

Óvári, I., Viczján, G., Erdei, T. D., Takács, B., Tarjányi, V., Zsuga, J., Szűcs, M., Szilvássy, Z., Juhász, B., Gesztelyi, R.: The influence of the way of regression on the results obtained by the receptorial responsiveness method (RRM), a procedure to estimate a change in the concentration of a pharmacological agonist near the receptor.
Front. Pharmacol. 15, 1-18, (article identifier: 1375955), 2024.

doi DEA WoS Scopus

Journal metrics:

Q1 Pharmacology

Q1 Pharmacology (medical)

2023

Viczján, G., Óvári, I., Erdei, T. D.: A kannabidiol és az adenozinerg rendszer kapcsolata.
Eü. Innov. Szle. 2 (2), 8-13, 2023.

DEA

2022

10.

Óvári, I., Szilágyi, V., Viczján, G., Lampé, N., Bege, M., Borbás, A., Herczeg, P., Juhász, B., Gesztelyi, R., Erdei, T. D.: Egy újonnan szintetizált adenozin analóg, a hipoxantin-triciklánó hatása izolált patkány bal és jobb pitvaron.
Eü. Innov. Szle. 1 (1), 9-16, 2022.

DEA

11.

Viczján, G., Szilágyi, A., Takács, B., Óvári, I., Szekeres, R., Tarjányi, V., Erdei, T. D., Teleki, V., Zsuga, J., Szilvássy, Z., Juhász, B., Varga, B., Gesztelyi, R.: The effect of a long-term treatment with cannabidiol-rich hemp extract oil on the adenosinergic system of the Zucker Diabetic Fatty (ZDF) rat atrium.
Front. Pharmacol. 13, 1-12, (article identifier: 1043275), 2022.

doi DEA WoS Scopus

Journal metrics:

Q1 Pharmacology

Q1 Pharmacology (medical)

2021

12.

Viczján, G., Erdei, T. D., Óvári, I., Lampé, N., Szekeres, R., Bombicz, M., Takács, B., Szilágyi, A., Zsuga, J., Szilvássy, Z., Juhász, B., Gesztelyi, R.: A Body of Circumstantial Evidence for the Irreversible Ectonucleotidase Inhibitory Action of FSCPX, an Agent Known as a Selective Irreversible A1 Adenosine Receptor Antagonist So Far.
Int. J. Mol. Sci. 22 (18), 1-21, (article identifier: 9831), 2021.

doi DEA WoS Scopus

Journal metrics:

Q2 Catalysis

Q1 Computer Science Applications

Q1 Inorganic Chemistry

Q1 Medicine (miscellaneous)

Q2 Molecular Biology

Q1 Organic Chemistry

Q1 Physical and Theoretical Chemistry

D1 Spectroscopy

2019

13.

Szabó, A. M., Viczján, G., Erdei, T. D., Simon, I., Kiss, R., Szentmiklósi, J. A., Juhász, B., Papp, C., Zsuga, J., Pintér, Á., Szilvássy, Z., Gesztelyi, R.: Accuracy and Precision of the Receptorial Responsiveness Method (RRM) in the Quantification of A1 Adenosine Receptor Agonists.
Int. J. Mol. Sci. 20 (24), 1-14, (article identifier: 6264), 2019.

doi DEA WoS Scopus

Journal metrics:

Q2 Catalysis

Q1 Computer Science Applications

Q1 Inorganic Chemistry

Q1 Medicine (miscellaneous)

Q2 Molecular Biology

Q1 Organic Chemistry

Q1 Physical and Theoretical Chemistry

Q1 Spectroscopy

14.

Szabó, A. M., Erdei, T. D., Viczján, G., Kiss, R., Zsuga, J., Papp, C., Pintér, Á., Juhász, B., Szilvássy, Z., Gesztelyi, R.: An Advanced in silico Modelling of the Interaction between FSCPX, an Irreversible A1 Adenosine Receptor Antagonist, and NBTI, a Nucleoside Transport Inhibitor, in the Guinea Pig Atrium.
Molecules. 24 (12), 1-16, (article identifier: 2207), 2019.

doi DEA WoS Scopus

Journal metrics:

Q2 Analytical Chemistry

Q2 Chemistry (miscellaneous)

Q2 Drug Discovery

Q2 Medicine (miscellaneous)

Q3 Molecular Medicine

Q2 Organic Chemistry

Q1 Pharmaceutical Science

Q2 Physical and Theoretical Chemistry